Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Yoon Tae Jeen"

Article category

Keywords

Publication year

"Yoon Tae Jeen"

Original Articles

Artificial intelligence, epidemiology, methodology, or others

Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome
Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo
Clin Mol Hepatol 2021;27(3):463-473.
Published online February 15, 2021
DOI: https://doi.org/10.3350/cmh.2020.0351
Background/Aims
Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic syndrome.
Methods
Subjects aged between 30 and 64 years were prospectively enrolled in the Seoul Metabolic Syndrome cohort. Serum MFG-E8 levels were measured at baseline.
Results
A total of 556 subjects were included, comprising 279 women (50.2%) and 277 men (49.8%). Metabolic syndrome was diagnosed in 236 subjects (42.4%), and the mean MFG-E8 level of subjects with metabolic syndrome was significantly higher than that of subjects without metabolic syndrome (P<0.001). MFG-E8 level was significantly correlated with all metabolic syndrome components and pulse wave velocity (all P<0.05). Subjects were categorized into two groups according to the best MFG-E8 cut-off value as follows: group 1, MFG-E8 level <4,745.1 pg/mL (n=401, 72.1%); and group 2, MFG-E8 level ≥4,745.1 (n=155, 27.9%). At baseline, metabolic syndrome in group 2 was significantly more prevalent than in group 1 (63.9% vs. 34.2%, P<0.001). During median follow-up of 17 months, metabolic syndrome developed in 122 (38.1%) subjects among 320 subjects without it at baseline. The incidence of metabolic syndrome in group 2 was significantly higher than that in group 1 (55.4% vs. 34.5%, P=0.003). On multivariate analysis, MFG-E8 level ≥4,745.1 pg/mL was an independent predictor for diagnosis and development of metabolic syndrome after adjusting other factors (all P<0.05).
Conclusions
Serum MFG-E8 level is a potent biomarker for the screening and prediction of metabolic syndrome.

Citations

Citations to this article as recorded by  Crossref logo
  • Exploring the potential of MFG-E8 in neurodegenerative diseases
    Dan Li, Wang Rongchun, Weihong Lu, Ying Ma
    Critical Reviews in Food Science and Nutrition.2025; 65(28): 5565.     CrossRef
  • Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice
    Volodymyr P. Tryndyak, Rose A. Willett, Zhuolin Song, Kostiantyn Dreval, Jennifer M. Hughes Hanks, Mark I. Avigan, Fred A. Wright, Frederick A. Beland, Ivan Rusyn, Igor P. Pogribny
    Toxicology and Applied Pharmacology.2025; 502: 117442.     CrossRef
  • Elevated circulating HHIP levels in patients with metabolic syndrome
    Jingwei Lei, Yu Yang, Yerui Lai, Dongfang Liu, Cong Wang, Weiwei Xu, Ke Li, Shengbing Li, Mengliu Yang, Ling Li
    Biochemical and Biophysical Research Communications.2024; 736: 150877.     CrossRef
  • MFGE-8 identified in fetal mesenchymal-stromal-cell-derived exosomes ameliorates acute hepatic failure pathology
    Adriana Psaraki, Dimitra Zagoura, Lydia Ntari, Manousos Makridakis, Christina Nikokiraki, Ourania Trohatou, Konstantina Georgila, Christos Karakostas, Ioanna Angelioudaki, Anastasios G. Kriebardis, Roberto Gramignioli, Stratigoula Sakellariou, Maria Xilou
    iScience.2023; 26(11): 108100.     CrossRef
  • Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD
    Rania Dagher, Paul Fogel, Jingya Wang, David Soussan, Chia-Chien Chiang, Jennifer Kearley, Daniel Muthas, Camille Taillé, Patrick Berger, Arnaud Bourdin, Cécile Chenivesse, Sylvie Leroy, Gary Anderson, Alison A. Humbles, Michel Aubier, Roland Kolbeck, Mar
    PLOS ONE.2022; 17(12): e0277357.     CrossRef
  • 10,925 View
  • 186 Download
  • 5 Web of Science
  • Crossref
Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels
Dong Jin Kim, Hyun Seok Kang, Hyuk Soon Choi, Hye Jin Cho, Eun Sun Kim, Bora Keum, Hyonggin An, Ji Hoon Kim, Yeon Seok Seo, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
Korean J Hepatol 2011;17(2):130-138.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.130
Background/Aims

Several studies suggested that serum cystatin C (CysC) is more useful than serum creatinine (Cr) for the assessment of renal function in patients with liver cirrhosis. This study evaluated the clinical significance of CysC in patients with cirrhotic ascites and normal Cr level.

Methods

We enrolled patients with cirrhotic ascites and a normal serum Cr level (<1.2 mg/dL). GFR was measured by 99mTc-DTPA renal scan. Serum Cr, CysC, and Cr clearance (CCr) were measured on the same day. Significant renal impairment and severe renal impairment were defined as GFR <60 mL/min and GFR <30 mL/min, respectively.

Results

Eighty-nine patients with cirrhotic ascites were enrolled in the study (63 men and 26 women; age, 55±11 years). Forty-seven (52.8%) and 42 (47.2%) patients were in Child-Pugh grade B and C, respectively. Serum Cr and CysC levels and GFR were 0.8±0.2 mg/dL, 1.1±0.3 mg/L, and 73.4±25.5 mL/min, respectively. Significant and severe renal impairment were noted in 28 (31.5%) and 2 (2.2%) patients, respectively. GFR was well correlated with serum Cr, CysC, and e-GFRMDRD, while it was not correlated with e-GFRC&G. In multivariate analysis, only CysC was significantly correlated with GFR (β, 45.620; 95% CI, 23.042-68.198; P<0.001). Serum CysC level was the only independent predictor for significant renal impairment.

Conclusions

Significant renal dysfunction was not rare in patients with cirrhotic ascites, even their serum Cr level is normal. Serum CysC is a useful marker for detecting significant renal dysfunction in these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Diagnostic value of serum TGF-β1 and CysC in type 2 diabetic kidney disease: a cross-sectional study
    Yi Kang, Qian Jin, Mengqi Zhou, Huijuan Zheng, Xiaobin Li, Aoshuang Li, Jing Wei Zhou, Jie Lv, Yaoxian Wang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Zonula occludens 1 as a novel biomarker in decompensated alcoholic cirrhosis with hepatorenal syndrome
    Balasubramaniyan Vairappan, Raj Kumar, Mukta Wyawahare
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Improved outcomes of kidney after liver transplantation after the implementation of the safety net policy
    Rose Mary Attieh, Ramez M. Ibrahim, Peter Ghali, Andrew Keaveny, Kristopher Croome, David Hodge, Launia White, Hani M. Wadei
    Liver Transplantation.2024; 30(6): 582.     CrossRef
  • The diagnostic and prognostic utility of serum cystatin C and angiopoietin 2 in patients with liver cirrhosis complicated by acute kidney injury
    Ahmed M. Abd El Wahab, Abeer Awadeen, Mostafa M. Mansour, Rasha Shemies
    Therapeutic Apheresis and Dialysis.2023; 27(3): 419.     CrossRef
  • Role of Novel Kidney Biomarkers in Patients With Cirrhosis and After Liver Transplantation
    Sumeet K. Asrani, Nagasri Shankar, Briget da Graca, Mitra K. Nadim, Andres Cardenas
    Liver Transplantation.2022; 28(3): 466.     CrossRef
  • Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients
    Fathia Elsayed Asal, Mohamed Yousef, Hend Atteya Abdelkhalek Abdraboh, Sherief Abd-Elsalam, Ahmed Abdelaziz Abdelaziz Shama, Mohamed Elbahnasawy, Mohammed H Elnaggar, Hesham Ahmed Alsrogy, Heba Elashry
    The Open Biomarkers Journal.2022;[Epub]     CrossRef
  • Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinine‐Based and Cystatin C–Based Equations: Systematic Review and Meta‐Analysis
    Prianka Singapura, Tsung‐Wei Ma, Naveed Sarmast, Stevan A. Gonzalez, François Durand, Rakhi Maiwall, Mitra K. Nadim, John Fullinwider, Giovanna Saracino, Claire Francoz, Rebecca Sartin, James F. Trotter, Sumeet K. Asrani
    Liver Transplantation.2021; 27(11): 1538.     CrossRef
  • Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure
    Praveen Jha, Ashish Kumar Jha, Vishwa Mohan Dayal, Sanjeev Kumar Jha, Amarendra Kumar
    Indian Journal of Gastroenterology.2021; 40(6): 563.     CrossRef
  • Serum cystatin C unmasks renal dysfunction in cirrhosis and performs better in estimation of glomerular filtration rate
    Balaraman Velayudham, RemiGeorge Thomas, C Vasudevan, RP Senthilkumar, Thirumalvalavan, Murugesan
    Saudi Journal of Kidney Diseases and Transplantation.2020; 31(6): 1320.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients
    Dong Wang, Jia-Fu Feng, An-Qun Wang, Yu-Wei Yang, Yun-Shuang Liu
    Medicine.2017; 96(20): e6949.     CrossRef
  • How to evaluate renal function in stable cirrhotic patients
    Florencia I. Aiello, Magdalena Bajo, Fernanda Marti, Carlos G. Musso
    Postgraduate Medicine.2017; 129(8): 866.     CrossRef
  • Appréciation du débit de filtration glomérulaire et de la dysfonction rénale chez le cirrhotique
    C. Mousseaux, A. Bouguerba, S. Ayed, J. Barchasz, M. Boukari, D. Goldgran-Toledano, C. Bornstain, F. Vincent
    Réanimation.2016; 25(S3): 137.     CrossRef
  • Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis
    Mahmoud Omar, Wael Abdel-Razek, Gamal Abo-Raia, Medhat Assem, Gasser El-Azab
    International Journal of Hepatology.2015; 2015: 1.     CrossRef
  • GFR Estimating Equations and Liver Disease
    Tomasz Beben, Dena E. Rifkin
    Advances in Chronic Kidney Disease.2015; 22(5): 337.     CrossRef
  • Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine
    Bilyana Teneva, Emiliya Karaslavova
    Open Medicine.2014; 9(5): 625.     CrossRef
  • Update on Cystatin C: Incorporation Into Clinical Practice
    Michael G. Shlipak, Monica D. Mattes, Carmen A. Peralta
    American Journal of Kidney Diseases.2013; 62(3): 595.     CrossRef
  • Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation
    Jeffrey C Sirota, Angela Walcher, Sarah Faubel, Alkesh Jani, Kim McFann, Prasad Devarajan, Connie L Davis, Charles L Edelstein
    BMC Nephrology.2013;[Epub]     CrossRef
  • Impact of creatinine production on the agreement between glomerular filtration rate estimates using cystatin C-derived, and 4- and 6-variable Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equ
    Esperanza F. Hermida-Cadahia, Natalia Lampon, J. Carlos Tutor
    Upsala Journal of Medical Sciences.2012; 117(4): 402.     CrossRef
  • Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury
    W. Stephen Waring, Alasdair Moonie
    Clinical Toxicology.2011; 49(8): 720.     CrossRef
  • 12,545 View
  • 89 Download
  • Crossref